nightprowler7
Well-known Member
How many more times are you going to edit your post? I thought you were the all knowing expert? You contribute nothing to a discussion. You are just a big mouth loser who ironically tells others they need to read more.Dumbass, you have absolutely no knowledge about how the human body works. I told you before: Speak less, read more and you might actually learn something.
Your ignorance really comes through when you speak.
I am not a fan of the Reddit and PGB Karen’s, but it is their attitudes, not their serious medical conditions I have an issue with!
Also, I am sure your post about purchasing 500g of product for personal use looks harmless to LE.
GLP-1 agonists: Roughly half of the pounds lost are in the form of muscle protein
I saw this in a recent article by Patrick Arnold: "GLP-1 agonists were a breakthrough in obesity treatment as no other obesity drugs ever came close to delivering the dramatic weight loss that they could. There is one problem with GLP-1 agonist promoted weight loss though, and that is the fact...
thinksteroids.com
From Millard himself-
I think the mainstreamization of drugs like semaglutide, tirzepatide, and retatrutide could have a big impact on the bodybuilding/AAS-using community.
Firstly, AAS users have always been stigmatized by society in no small part due to the widespread use of injectable compounds by bodybuilders/athletes.
If a significant percentage (and even a majority) of the population starts using "accepted" injectable drugs like the GLP-1 agonists, for health, performance-, and/or image-enhancing reasons, then injectable drugs will become more normalized and the needle stigma will slowly start to fade. And I guess this is kind of a positive thing
OTOH, there will also likely be negative fall out for the AAS-using bodybuilding community.
Secondly, as we are currently seeing, many domestic and international AAS/GH underground sources are adding semaglutide, etc. to their lineups. After all, it fits in perfectly with the subculture of PIEDs.
Thirdly, this is a potential multi-billion dollar profit bonanza for bigpharma unlike any other. In the past, bigpharma showed little interest in the underground AAS sources supplying the bodybuilding community because it didn't really have a major financial impact on the profits.
It's different with GLP-1 agonists. Bigpharma will aggressively seek to protect their profits. You could see them going after pharmacies that import foreign versions, compounding pharmacies, research chemical companies, pharmaceutical diversion, etc. either directly when possible or via law enforcement action when necessary.
And because traditional underground suppliers of AAS will have these drugs on their menu, they could become increasingly and more aggressively target by LE in the future.